CN Patent

CN112220748A — 地氯雷他定口服液制剂及其制备方法

Assigned to ALPHA PHARMACEUTICAL CO LTD JIANGSU PROVINCE · Expires 2021-01-15 · 5y expired

What this patent protects

本发明属于制药领域，特别是涉及口服液制剂领域，更为具体的说是涉及地氯雷他定口服液制剂及其制备方法，所述地氯雷他定口服制剂为水剂，由地氯雷他定活性组分、稳定剂、药学上可接受的辅料及溶剂水组成。本发明公开的地氯雷他定口服溶液剂及其制备方法，制备工艺简单，患者依从性良好。通过影响因素试验和加速试验可知，采用本专利处方工艺可制得质量稳定的产品。

USPTO Abstract

本发明属于制药领域，特别是涉及口服液制剂领域，更为具体的说是涉及地氯雷他定口服液制剂及其制备方法，所述地氯雷他定口服制剂为水剂，由地氯雷他定活性组分、稳定剂、药学上可接受的辅料及溶剂水组成。本发明公开的地氯雷他定口服溶液剂及其制备方法，制备工艺简单，患者依从性良好。通过影响因素试验和加速试验可知，采用本专利处方工艺可制得质量稳定的产品。

Drugs covered by this patent

Patent Metadata

Patent number
CN112220748A
Jurisdiction
CN
Classification
—
Expires
2021-01-15
Drug substance claim
No
Drug product claim
No
Assignee
ALPHA PHARMACEUTICAL CO LTD JIANGSU PROVINCE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.